Our Core Values
AbbVie’s identity is created by the work we perform, which includes developing innovative medicines, investing in our pipeline, and giving back to help communities become healthier and more vibrant. Most importantly, our shared ideas that have evolved naturally since AbbVie’s inception have created our identity.
Our mission is significant, and our path is well-defined. We are committed to making a significant difference in people’s lives through the new medications and solutions we develop together. This is fueled by our human compassion, commitment to innovation and inclusivity, community service, and unwavering integrity at the core of what we do. Our company culture is dedicated to operating with integrity, supporting diversity and inclusion, supporting our community, fostering innovation, and changing people’s lives. Our values are the bedrock of our organisation. They bring us together, guide our decisions, and motivate us.
We care strongly for our patients, their families, our colleagues, and our communities as one AbbVie team. We try to do the right thing at all times, pursuing the highest quality, compliance, safety, and performance standards. We invest and innovate persistently in everything we do to address unmet needs, developing novel medicines and healthcare practises for a healthier world.
Our employees around the world value varied backgrounds and opinions and treat everyone with dignity and respect, allowing us to all achieve our full potential. We take pride in doing our share to serve and support our communities while also protecting the environment, leaving a lasting impression on the healthcare industry and beyond.
What we do isn’t easy, but we keep going because the results inspire hope and change lives every day. Getting patients to better satisfy with their prescribed drug therapy and encouraging the development of new drugs can balance or even lower, overall health care spending. Innovation in the pharmaceutical industry can boost the output of an economy by reducing lost productivity due to disease and sickness.
Research and innovation are the keystones of AbbVie business. Through dynamic and collaborative approach the company advances leading-edge. This allows AbbVie to find enhanced solutions for those diseases which are challenging.
The firm concentrates on discovering, developing and delivering drugs in therapeutic areas where it has proven expertise and can make an impact. This includes:
AbbVie was created in 2013, but it has a long history. Though they have a common past and excellent possibilities for future success, the company split apart from Abbott in 2013.
The name of the company indicates its ties to both the past and the future. AbbVie created a new type of business when it became its own corporation: a biopharmaceutical company. The corporation combines a pharmaceutical business’s stability, worldwide scale, resources, and commercial capabilities with a biotech’s focus and culture.
The company employs 29,000 people worldwide, including scientists, researchers, communicators, manufacturing professionals, and regulatory experts. The organisation devised novel solutions to today’s health problems, ranging from life-threatening illnesses to chronic illnesses.
The company will focus on a specific condition that is difficult to treat so that they can use their R&D experience to advance science. The organisation is constantly working to develop solutions that have a positive impact in addition to curing illness.
AbbVie’s workforce engages with peers, academics, clinical experts, front-line practitioners, governments, and advocacy groups to navigate the patient journey, which drives the firm to create and deliver novel solutions that make a difference.
Working at AbbVie is more than a job for the AbbVie team because it allows them to help people all over the world live better lives. When the stakes are as high as a patient’s health, the finest ideas must rise to the top, regardless of where they come from.
The company’s products are approved in individual countries for specific uses and the information provided is governed by local regulations. Product availability, name and indicated use may vary by country.
AndroGel (testosterone gel)
BIAXIN Filmtab (clarithromycin)
BIAXIN XL Filmtab (clarithromycin extended-release tablets)
BIAXIN Granules (clarithromycin)
Depakote (divalproex sodium) tablets
Depakote ER (divalproex sodium extended-release tablets)
Depakote Sprinkle Capsules (divalproex sodium delayed-Â release capsules)
Science Rocks! The Plastic Eating Enzyme that Could Save our Environment
Science Rocks features AbbVie employees who share interesting research and why it matters. In this month’s feature, Joel Melnick, executive medical director of general medicine, AbbVie, shares an article about an enzyme that may be able to break down some of the 8.3 billion tons of plastic that has been clogging up the worlds landfills for decades.
Over the next two years, other scientific groups have tried to understand the way the protein worked. Just recently, one of these scientific groups used a high-resolution X-ray to identify individual amino acids responsible for digesting PET and degrading the plastic. He then adjusted the amino acids to speed up the degradation from a month to a few days.
Rick Gonzalez is the Chairman of the Board and Chief Executive Officer of AbbVie, a worldwide biopharmaceutical firm with over 29,000 employees and a presence in over 175 countries. Mr. Gonzalez was a 30-year Abbott employee prior to AbbVies’ departure from Abbott. He led the global pharmaceutical business, including commercial operations, research and development, and production, as Executive Vice President, Pharmaceutical Products Group. Prior to a temporary retirement, he also served as President and Chief Operating Officer.
Source : AbbVie